Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01237067

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Study identifier: NCT01237067
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Olaparib (AstraZeneca)

Eligibility:

Patients with recurrent/refractory breast cancer that is metastatic or unresectable and for which standard therapies do not exist or are no longer effective. BRCA1/2 mutation carriers will be eligible with any metastatic disease.

Type of study:

Phase I study

Treatment:

Breast cancer patients who enroll will receive one of several possible schedules of olaparib plus carboplatin.

Study site:

Maryland

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
Contact: Laura D.Otten, R.N., B.S.N., O.C.N.
Medical Oncology Referral Coordinator 301-451-1228
1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

 

Page updated 03/21/11